Modern people doing business, graphs and charts being demonstrated on the screen of a touchpad

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) shares traded on -1.41% below secure line and closed at $20.26. The stock exchanged hands 17.28 Million shares versus average trading capacity of 11.45 Million shares. It has a market cap of $20.78 Billion.

Wall Street analysts are predicting that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will report earnings per share of $0.54 in their quarterly report. For the current quarter Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has high EPS estimates of $0.68 in contradiction of low EPS estimates of $0.41. However a year ago for the same quarter the company has reported $0.93 EPS. Average estimation for the current quarter has been provided by 19 analysts.

Investors as well as the sell-side will be paying close attention to how the actual numbers compare with the estimates. Earnings surprises can have a huge impact on a company’s stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock’s price, but also to a gradual increase over time. Hence, it’s not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.

A large surprise factor in either direction typically can lead to a significant swing in the stock price in the hours and days after the report. Previously Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.14 with surprise factor of 25.9%.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has average revenue estimates of $4.53 Billion, compared to low analyst estimates of $4.28 Billion and high estimates of $4.76 Billion for the current quarter. A total number of 17 analysts provided estimations over revenues. For the current year the company’s revenue estimates are $18.85 Billion compared to low analyst estimates of $18.57 Billion and high estimates of $19.05 Billion according to the prediction of 20 analysts.

Taking a broader look at the analyst consensus, according to 16 analysts Teva Pharmaceutical Industries Ltd (NYSE:TEVA)’s price will reach at $23.19 during 52 weeks. Its minimum price target estimates has been figured out at $15 while the maximum price target forecast is established at $30.

On the other hand Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has Relative Strength Index (RSI 14) of 32.99 along with Average True Range (ATR 14) of 0.75. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock’s price movement. The RSI value will always move between 0 and 100; the value will be 0 if the stock falls on all 14 days, and 100, if the price moves up on all the days) as suggested by J Welles Wilder. In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. The level of 50 represents neutral market momentum and corresponds with the center line in other oscillators such as MACD (Moving Average Convergence/Divergence). The average true range (ATR) is a measure of volatility introduced by Welles Wilder.

Consequently Teva Pharmaceutical Industries Ltd (NYSE:TEVA)’s weekly and monthly volatility is 3.12%, 2.88% respectively.